Values First Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-27,262
| Closed | -$41.2K | – | 183 |
|
|
2023
Q2 | $41.2K | Buy |
27,262
+580
| +2% | +$921 | 0.02% | 161 |
|
|
2023
Q1 | $46.6K | Buy |
26,682
+814
| +3% | +$1.37K | 0.03% | 194 |
|
|
2022
Q4 | $48.9K | Sell |
25,868
-23
| -0.1% | -$51 | 0.03% | 147 |
|
|
2022
Q3 | $54K | Buy |
25,891
+24,142
| +1,380% | +$102K | 0.04% | 148 |
|
|
2022
Q2 | $8K | Sell |
1,749
-49
| -3% | -$320 | 0.01% | 153 |
|
|
2022
Q1 | $19K | Buy |
1,798
+263
| +17% | +$3.2K | 0.01% | 159 |
|
|
2021
Q4 | $23K | Sell |
1,535
-296
| -16% | -$7.01K | 0.01% | 166 |
|
|
2021
Q3 | $54K | Buy |
1,831
+63
| +4% | +$1.78K | 0.04% | 142 |
|
|
2021
Q2 | $60K | Sell |
1,768
-33
| -2% | -$1.23K | 0.04% | 143 |
|
|
2021
Q1 | $75K | Buy |
1,801
+109
| +6% | +$6.77K | 0.06% | 139 |
|
|
2020
Q4 | $102K | Sell |
1,692
-132
| -7% | -$14.3K | 0.08% | 139 |
|
|
2020
Q3 | $243K | Buy |
1,824
+211
| +13% | +$35.3K | 0.22% | 122 |
|
|
2020
Q2 | $272K | Sell |
1,613
-30
| -2% | -$5K | 0.27% | 110 |
|
|
2020
Q1 | $236K | Buy |
1,643
+782
| +91% | +$239K | 0.28% | 103 |
|
|
2019
Q4 | $284K | Buy |
+861
| New | +$395K | 0.27% | 106 |
|
Values First Advisors's NBRV Position: Q3 2023 in Review
Values First Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2023, closing a stake of 27,262 shares — an estimated $41.2K sold.
Values First Advisors first reported a position in NBRV in Q4 2019 and held it in 15 quarters. The position peaked at $284K in Q4 2019. 0 funds tracked by Wall St. Rank hold NBRV as of Q3 2023.
- Values First Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2023 after selling out during the quarter.
- Values First Advisors sold 27,262 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2023, an estimated $41.2K.
- Values First Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2019 and held it in 15 quarters.
- Values First Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $284K in Q4 2019.
- 0 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2023.
Based on Values First Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.